Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790907 · ClinicalTrials.gov registry record · Phase 4
Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 3,235
- Enrollment target
NCT00790907 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 3,235 participants.
The verdict
NCT00790907, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 3,235 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety of two different dose regimens of unfractionated heparin (UFH) during a percutaneous coronary intervention (PCI) procedure in patients with UA (unstable angina)/NSTEMI (non ST segment elevation myocardial infarction) who have been initially treated with fondaparinux.
Interventions
- DRUG fondaparinux background and standard dose UFH
- DRUG Fondaparinux background and low dose heparin
- DRUG Open label fondaparinux
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,235 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00790907
The ClinicalTrials.gov registry entry for NCT00790907 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 3,235 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which fondaparinux background and standard dose UFH is the first listed.
NCT00790907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00790907 about?
NCT00790907 is a clinical study titled "Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)". The purpose of this study is to compare the safety of two different dose regimens of unfractionated heparin (UFH) during a percutaneous coronary intervention (PCI) procedure in patients with UA (unstable angina)/NSTEMI (non ST segment elevation myocardial infarction) who have been initially treated ...
What is the current status of trial NCT00790907?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 3,235 participants. The study started on 2009-02. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00790907?
The interventions under investigation include: fondaparinux background and standard dose UFH (DRUG), Fondaparinux background and low dose heparin (DRUG), Open label fondaparinux (DRUG).
Who is sponsoring clinical trial NCT00790907?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.